iCAD to Report First Quarter 2022 Financial Results on Wednesday, May 11
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
iCAD, Inc. (NASDAQ: ICAD), a leader in cancer detection and therapy solutions, announced it will release its financial results for Q1 2022 on May 11, 2022, after market close. The company will also host a conference call at 4:30 PM ET the same day, where details on financial performance will be discussed. Interested parties can join via the provided domestic and international numbers or through a webcast. The upcoming financial results are anticipated to provide insights into the company’s growth and strategic direction.
Positive
- Scheduled financial results release for Q1 2022, indicating proactive communication with investors.
- Hosting a conference call which can enhance shareholder engagement and transparency.
Negative
- None.
Details
News Market Reaction – ICAD
The recorded move for ICAD in the trading session of this news was -4.90%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NASHUA, N.H., April 27, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the first quarter ended March 31, 2022, after the market close, and host a conference call at 4:30 PM Eastern Time on Wednesday, May 11.
| Wednesday, May 11th at 4:30 PM ET | |
| Domestic: | 888-506-0062 |
| International: | 973-528-0011 |
| Conference ID: | 728427 |
| Webcast: | https://www.webcaster4.com/Webcast/Page/2879/45416 |
About iCAD, Inc.
Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit www.icadmed.com.
Contact:
Media Inquiries:
Jessica Burns, iCAD
+1-201-423-4492
jburns@icadmed.com
Investor Inquiries:
iCAD Investor Relations
ir@icadmed.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.